LAUSR

90Background: Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity in NSCLC patients. Methods: A retrospective review of data from 20 patient records were used to describe the response of patients with NSCLC receiving treatment with Nivolumab after failing chemotherapy. Two patients were too early to evaluate. Results: A total of 18 patients (pts) (10 males and 8 females) were included in the analysis. The median age was 66 years (range 46-85). Adenocarcinoma was documented in 15 pts and squamous cell carcinoma in 3 pts. A Ros-1 positive mutation was documented in 1 pt, 3 EGFR positive mutations were recorded and no pts tested positive for ALK. All pts failed frontline treatment: 14 pts failed platinum based chemotherapy and 4 pts failed TKI-inhibitors (3 on erlotinib and 1 on crizotinib). Pts received a median of 4 cycles of nivolumab (range 1-16). The performance status ranged from 0 to 2 (median...